Clinical Usefulness and Prognostic Significance of Interim 18F-FDG PET/CT for the Treatment of Peripheral T Cell Lymphomas
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Although interim 18F-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/computerized tomography (CT) scan has emerged as a powerful prognostic tool in predicting treatment outcome in Hodgkin's lymphoma (HL) and diffuse large B cell lymphoma (DLBCL), the positive predictive value (PPV) of interim PET/CT scanning has not been determined in patients with peripheral T cell lymphoma (PTCL). The sequential interim PET/CT will be prospectively investigated to determine whether it provided additional prognostic information and could be a positive predictable value for the treatment of PTCL.
| Condition |
|---|
|
Peripheral T Cell Lymphoma |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
- Progression-free survival [ Time Frame: From the treatment start time to the first recording of disease progression or death from any cause, which assessed up to 24 months. ] [ Designated as safety issue: No ]Patients whose disease did not progress would be censored using the date at which they were last known to show no progress.
| Estimated Enrollment: | 80 |
| Study Start Date: | August 2004 |
| Estimated Study Completion Date: | May 2012 |
| Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
Show Detailed Description Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
This study is the observational study for the response assessments on interim PET/CT during the treatment of peripheral T cell lymphomas. Thus, first analysis of clinical data will be performed at the time of 80 patients enrolled or after a median follow-up of more than 12 months.
Inclusion Criteria:
- Age above 18 years
- Histologically proven PTCLs except primary cutaneous/subcutaneous panniculitis
- ECOG performance status ≤ 2
- Patients who are available to be performed PET/CT at diagnosis
- No severe concomitant disease
Exclusion Criteria:
- Patients who did not undergo PET/CT scans at diagnosis
- Patients who have a primary CNS lymphoma
- Patients who have a HIV or HTLV-1
- Patients who could not receive primary chemotherapy
Contacts and Locations| Contact: Deok-Hwan Yang, M.D., Ph.D. | 82-61-379-7636 | drydh1685@gmail.com |
| Contact: Je-Jung Lee, M.D.,Ph.D. |
| Korea, Republic of | |
| Chonnam National University Hwasun Hospital | Recruiting |
| Hwasun-gun, Jeollanam-do, Korea, Republic of, 519-809 | |
| Contact: So-Young Lee, Nurse 82-61-379-7628 kaosin@naver.com | |
| Principal Investigator: Deok-Hwan Yang, M.D.,Ph.D. | |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT01470066 History of Changes |
| Other Study ID Numbers: | PET2005-01 |
| Study First Received: | November 3, 2011 |
| Last Updated: | November 10, 2011 |
| Health Authority: | Korea: Institutional Review Board |
Keywords provided by Chonnam National University Hospital:
|
peripheral T cell lymphomas interim PET/CT prognosis Positron-emission tomography/Computerized tomography |
Additional relevant MeSH terms:
|
Lymphoma Lymphoma, T-Cell Lymphoma, T-Cell, Peripheral Neoplasms by Histologic Type Neoplasms |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin |
ClinicalTrials.gov processed this record on May 22, 2013